fda bpc-157 warning letter 2024 2025 issued 25 letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of 5 GMP Lessons from 2025's
Description
Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: a randomised, crossover clinical trial
Who Might Benefit From B12 Shots
First, the confounding effect of age was eliminated through linear regression
Ready to explore peptide therapy
Teriflunomide in patients with relapsing-remitting forms of multiple sclerosis
Another major indication for using it is the problem with balance and coordination that cause unsteady walking and easy falling
